Noveome Biotherapeutics
PrivateLast Round
Seed Round
Aug 12, 2026
Total Funding Raised
$185.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Noveome Biotherapeutics operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series E round in April 2025.
Noveome Biotherapeutics is a biotechnology company that develops novel biotherapeutic products aimed at treating inflamed or damaged tissues through a synergistic combination of biologic components.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Noveome Biotherapeutics Comparables
Compare Noveome Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 82% | |
| Plakous Therapeutics | 81% | |
| EXO Biologics | 80% |
For institutional investors. Book with your work email.
Noveome Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Aug 12, 2026 | ||||
| Series E | Apr 23, 2025 | ||||
| Grant | Jun 23, 2021 | ||||
| Growth Equity | Sep 24, 2020 | ||||
| Grant | May 7, 2020 | ||||
Series D | Apr 9, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Noveome Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| University of Pittsburgh Investment Office | Seed |
| Carnegie Mellon University Investment Office | Seed |
| Miraki | Series E |
| U.S. Department of War | Grant |
| Commonwealth of Pennsylvania | Grant |
| MAK Capital One | Series E |
| Lancet Capital | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2026
Raised $7M in a Seed Round.
- Apr 23, 2025
$51M round led by MAK Capital One.
For institutional investors. Book with your work email.
Noveome Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Noveome Biotherapeutics's valuation, stock price, and market status.
Is Noveome Biotherapeutics a public or private company?
Noveome Biotherapeutics is a private company.
What is the current stock price of Noveome Biotherapeutics?
Noveome Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Noveome Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Noveome Biotherapeutics worth (valuation)?
Valuation information for Noveome Biotherapeutics is not publicly available.
Can I buy Noveome Biotherapeutics stock?
Noveome Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Noveome Biotherapeutics's last funding round?
Noveome Biotherapeutics's most recent funding round was Seed Round on August 12, 2026.
Who are the main investors in Noveome Biotherapeutics?
Key investors in Noveome Biotherapeutics include MAK Capital One, Lancet Capital.
Will Noveome Biotherapeutics IPO soon?
No public IPO plans have been announced for Noveome Biotherapeutics.
How can I track Noveome Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Noveome Biotherapeutics's shares on secondary markets.